Today, AD treatment is mainly aimed at increasing the level of the neurotransmitter acetylcholine by inhibiting acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), the enzymes responsible for acetylcholine’s hydrolysis. This evidence concerns the gene BCHE and Alzheimer disease.